StockFin.ai
/
Sign inTry Free

Tools

Search Companies
News & Filings
Insights & Articles
FeaturesComing Soon
Pricing

Senores Pharmaceuticals Limited (SENORES) — Board Meeting | 26 August 2026 (4 announcements)

· NSE 🟡 Notable Neutral
By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings
1Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Board approves new CS, independent director, ESOP scheme, and Mexico/Canada subsidiary plans
🔄 What Changed
Added independent director and compliance officer; approved ESOP scheme; announced Mexico and Canada subsidiary incorporation plans
🔮 What's Next
The board approved the ESOP scheme subject to shareholder approval and regulatory clearances; incorporation of Mexico and Canada subsidiaries is pending further approvals and regulatory compliance
💡 Investor Takeaway
These appointments and expansion plans signal leadership strengthening and international growth ambitions, which may enhance long-term value but require shareholder approval for the ESOP scheme

Senores Pharmaceuticals announced board approvals on August 26, 2026, including the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, Mr. Viranchi Arvindbhai Shah as an Independent Director, adoption of the Employee Stock Option Scheme 2026, and plans to establish wholly owned subsidiaries in Mexico and Canada to expand international operations.

2Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Board approves new CS, independent director, ESOP scheme, and Mexico/Canada subsidiary plans
🔄 What Changed
Added new CS and independent director; approved ESOP scheme; announced Mexico and Canada subsidiary incorporation plans
🔮 What's Next
None
💡 Investor Takeaway
These appointments and expansion plans signal leadership strengthening and international growth ambitions, potentially enhancing long-term value but requiring shareholder approval for ESOP and subsidiaries.

Senores Pharmaceuticals announced board approvals on August 26, 2026, including the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, Mr. Viranchi Arvindbhai Shah as an Independent Director, adoption of the Employee Stock Option Scheme 2026, and plans to establish wholly owned subsidiaries in Mexico and Canada to expand international operations.

3Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Board approves new Company Secretary, Independent Director, ESOP 2026, and Mexico/Canada subsidiaries
🔄 What Changed
Added Company Secretary and Compliance Officer; appointed Independent Director; approved ESOP 2026; approved Mexico and Canada subsidiary incorporations
💡 Investor Takeaway
These appointments and expansions signal stronger governance and global growth plans, potentially boosting investor confidence in long-term strategy.

Senores Pharmaceuticals announced board approvals on August 26, 2026, including the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, Mr. Viranchi Arvindbhai Shah as an Independent Director, adoption of the Employee Stock Option Scheme 2026, and plans to establish wholly owned subsidiaries in Mexico and Canada. The board also designated key managerial personnel for materiality decisions. These changes strengthen governance and expand international operations.

4Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Board approved key appointments and international expansion plans
🔄 What Changed
Added independent director and company secretary; approved stock option scheme; announced Mexico and Canada subsidiary incorporation
💡 Investor Takeaway
These moves strengthen governance and signal strategic expansion into global markets.

Senores Pharmaceuticals announced board approvals on August 26, 2026, including the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, Mr. Viranchi Arvindbhai Shah as an Independent Director, adoption of the Employee Stock Option Scheme 2026, and plans to establish wholly owned subsidiaries in Mexico and Canada to expand international operations.

📊 Stock Analysis — SENORES✨ Ask AI About This

About Senores Pharmaceuticals Limited (SENORES)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹6,226.21 CrP/E: 47.6ROE: 13.5%ROCE: 15.6%

View full SENORES stock details →

📡 Get AI alerts when SENORES files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SENORES — Free

💡 Ask AI about this filing

"When will shareholders vote on the ESOP scheme?""What is the expected timeline for Mexico subsidiary incorporation?""How will the new director impact governance?"
Ask AI Free →

📊 More SENORES filings

See all SENORES filings →

🔥 Also filed on 26 August 2026

ORIENTCEMOrient Cement LimitedCorporate ActionIRBIRB Infrastructure Developers LimitedCorporate ActionEUROTEXINDEurotex Industries and Exports LimitedAnnual ReportINNOVISIONInnovision LimitedAnnouncementMOLDTECHMold-Tek Technologies LimitedCorporate ActionMOTHERSONSamvardhana Motherson International LimitedCorporate Action
View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SENORES files new disclosures

Track SENORES filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SENORES — Free

Free account · 2 AI queries/day